Compare Ascendis Pharma A/S (ASND) vs NetFlix Inc (NFLX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs NetFlix Inc — how do they compare? Ascendis Pharma A/S trades at $270.45 (market cap $17.74B), while NetFlix Inc trades at $73.93 (market cap $308.95B). The key difference: NetFlix Inc is far larger — about 17.4× Ascendis Pharma A/S's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, NetFlix Inc nearer its low. Which is the better fit depends on your goals.
| ASND | NFLX | |
|---|---|---|
Market Cap | $17.74B | $308.95B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $127.42 |
52-Week Low | $163.32 | $70.91 |
Enterprise Value | $18.11B | $311.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Netflix (NFLX) trades at $73.37, down 2.78% on the day, reflecting recent bearish momentum amid a mixed technical backdrop. Fundamentally, the company shows strong profitability with a 28.52% net income margin and robust revenue growth, reaching $45.18B in 2025. Analyst consensus remains bullish with a $111.80 price target, though recent news highlights stock weakness despite business expansion in advertising and content.
The outlook for NFLX hinges on scaling its ad-supported tier and live sports initiatives, offering significant upside if execution succeeds. Risks include intense streaming competition and market sentiment shifts. With solid cash flow growth and high institutional confidence, the stock presents a value opportunity for long-term investors despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About NetFlix Inc
Netflix Inc. is an Internet subscription service for watching television shows and movies. Subscribers can instantly watch unlimited television shows and movies streamed over the Internet to their televisions, computers, and mobile devices and in the United States, subscribers can receive standard definition DVDs and Blu-ray Discs delivered to their homes.
Read more on NFLX →
